Ross Camidge, MD, PhD

Drs Camidge and Call discuss Dr Call's career path, which transitioned from community oncology to full-time phase 1 research within community practice.

Drs Camidge and Fleming discussed how Fleming's interest in biostatistics led to a multifaceted career in clinical trial design and analysis.

Camidge and Singer discuss how Singer's background in broadcasting and cable television has led to a career in promoting cancer awareness.

Drs Camidge and Blumenthal discussed Dr Blumenthal's experience serving on both sides of the oncology regulatory divide.

Drs Camidge and Socinski discussed the highlights of Dr Socinski's career trajectory and the personal influences that helped him arrive where he is today.

D. Ross Camidge, MD, PhD, discusses safety and efficacy data seen with neladalkib in TKI-naive and -pretreated patients with ALK-positive solid tumors.

Ross Camidge, MD, PhD, discusses a pivotal phase 2/3 clinical trial (ARROS-1) evaluating the efficacy and safety of zidesamtinib in patients with advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who have previously received tyrosine kinase inhibitor (TKI) therapy.

Drs Camidge and Culver discuss the highlights of Dr Culver's career, shaped by clinical practice, research, leadership, and patient advocacy.

Camidge and Lee discussed Lee's professional journey and personal insights gained from years of working at the intersection of clinical research and patient care.

Drs Camidge and Blue discussed Dr Blue’s journey into practicing medicine, and speciaffly how he settled on treating malignant hematologic conditions.

Camidge and Young discuss Young's career, which combined her passions for science and global engagement and led her to a Cancer Moonshot leadership role.

D. Ross Camidge, MD, PhD sat down with Liz O'Riordan, FRCS, PhD, who describes herself as a breast surgeon who has had breast cancer.

Camidge and Machos discussed Machos' early career transition from pre-med to sales, to her role in building strategic partnerships with key opinion leaders in oncology.

Drs Camidge and Lin discussed Dr Lin's work with brain metastases and her role in developing targeted therapies for breast cancer.

Drs Camidge and Rink discuss Dr Rink's career in medical physics and the importance of multidisciplinary collaboration to deliver optimal patient care.

Drs Camidge and Nechtman discuss Dr Nechtman's experience supporting and caring for his wife Laura during her lung cancer diagnosis and treatment.

D. Ross Camidge, MD, PhD, discusses the benefits of biomarker testing and the potential value of longitudinal testing in non–small cell lung cancer.

Drs. Camidge and Oxnard discuss novel EGFR inhibitors, the role of precision medicine in early cancer detection, and balancing clinical and industry roles.

Drs Camidge and Studts discuss Dr Studts' career in behavioral science and the importance of integrating lung cancer screening into primary care.

Drs Camidge and Eisen discuss Dr Eisen's dual career in academia and industry, the importance of aligning academic and clinical strengths, and how industry experience can enhance drug development.

Drs Camidge and Boire discuss Dr Boire's path to becoming a physician-scientist and how cellular biology research can improve outcomes for patients with cancer.

Drs Camidge and Redman discuss Dr Redman's role as a biostatistician at Fred Hutch, outlining her work in designing clinical trials.

Drs Camidge and Smylie discussed Dr Smylie’s experience treating patients who live in the Northwest Territories of Canada.

Drs Camidge and Gosain discuss how Dr Gosain harnessed social media to create a podcast with practice updates for up-and-coming oncology professionals.

Drs Camidge and McLaren discuss Dr McLaren’s journey to medical school and his experience as a clinical oncologist with expertise across disciplines.

Drs Camidge and Ney discuss Dr Ney’s journey to becoming a neurologic oncologist and his experience as a physician with Tourette syndrome.

Drs Camidge and Zirkelbach discuss Zirkelbach's first pharmacokinetics forays and her involvement with reforming dose optimization in drug development.

D. Ross Camidge, MD, PhD, and Kadrin Wilfong, MD discuss Wilfong's passion for continuing medical education (CME) and how CME events and resources can make a difference in the care of patients with cancer.

Camidge and Kahl reflect on the steps in Kahl’s communications career that paved the way for her to become a leader in the medical journalism field.